Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Generalised pustular psoriasis

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Acute pustular systemic crisis

Waves of widespread sterile pustules with painful inflammation, fever, tachycardia or malaise can cause fluid and protein loss, electrolyte disturbance, sepsis, respiratory failure, high-output cardiac failure and shock.

Action: Arrange same-day admission and urgent dermatology review, assess ABCDE and extent, culture before but never instead of treating suspected infection, monitor organ function and calcium, provide temperature, fluid, nutritional and skin support, and start specialist flare therapy without systemic corticosteroid withdrawal.

Synopsis

Recognise a generalised pustular psoriasis flare as a potentially fatal neutrophilic emergency, exclude infection and drug pustulosis, stabilise systemic complications, and apply current specialist systemic and spesolimab criteria safely.

  • Generalised pustular psoriasis causes widespread visible or superficial non-follicular pustules on inflamed skin with systemic illness; pustules are sterile unless secondary infection complicates them.
  • Pustules may be conspicuous cream-yellow in any skin tone, while background erythema can look red, violaceous, grey-brown or dusky and is assessed with warmth, tenderness and swelling.
  • Ask about established plaque or pustular psoriasis, previous flares, pregnancy, infection, hypocalcaemia, medicine exposure and abrupt withdrawal of systemic corticosteroid or other psoriasis treatment.
  • Do not dismiss fever and neutrophilia as infection or psoriasis alone: culture plausible sites and blood in systemic illness while simultaneously treating physiological compromise.
  • AGEP is the key medicine-related mimic, often appearing rapidly after a drug with superficial flexural pustules, eosinophilia and quicker resolution after withdrawal; overlap still needs biopsy and specialist review.
  • Admit significant widespread disease for repeated temperature, haemodynamic, respiratory, urine, blood-count, renal, liver, albumin, calcium and inflammatory assessment.
  • Supportive care includes a warm environment, gentle bland emollient, fluid and electrolyte correction, nutrition, thrombosis and pressure care, and prompt directed antimicrobial treatment when infection is suspected.
  • Never use or withdraw systemic corticosteroid casually in psoriasis; withdrawal is a recognised precipitant and rescue treatment needs an experienced dermatology team.
  • NICE TA1070 recommends intravenous spesolimab for defined moderate-to-severe adult flares under specific GPPGA, fresh-pustule and body-surface criteria, including a separate subsequent-flare rule.
  • The current intravenous SmPC licenses flare treatment from age 12, but NICE funding is narrower; licence, appraisal, life-threatening-disease evidence limits and local specialist access must all be distinguished.

Key red flags

Hypotension, hypoxia, confusion, oliguria, rapidly spreading painful pustulation, hypothermia or high fever, severe oedema, tetany, mucosal involvement, pregnancy, childhood, frailty, neutropenia, suspected sepsis or respiratory symptoms requires critical-care-level reassessment and urgent specialist treatment.

Organ-threatening flare

Hypotension, hypoxia, confusion, oliguria, marked calcium disturbance, tetany, extensive erosion or rapidly escalating oxygen and fluid need indicates critical illness.

Investigation priorities

01
Full blood count and differentialFirst step

Quantify neutrophilic inflammation and identify eosinophilia, cytopenia or infection risk.

Management branches

First-line emergency careAdmit, stabilise and sample

Widespread pustulation is accompanied by systemic symptoms, rapid progression or diagnostic uncertainty.

  1. Assess ABCDE, core temperature, haemodynamics, oxygen need, mental state, pain, extent, mucosae and urine output and involve dermatology immediately.
  2. Obtain full blood count, renal, liver, albumin, calcium, magnesium, CRP and appropriate cultures, biopsy a fresh lesion and document the complete medicine timeline.
  3. Nurse warm, use gentle bland barrier care, correct fluid and electrolytes against serial findings, support nutrition and treat clinically suspected sepsis promptly.
  4. Avoid abrupt systemic corticosteroid withdrawal and escalate pregnancy, organ failure, respiratory deterioration or shock to the relevant acute and critical-care teams.

Key medicines

Intravenous spesolimabGive 900 mg as a single intravenous infusion over 90 minutes; if flare symptoms persist, one additional 900 mg dose may be given 1 week later.Do not initiate with clinically important active infection or active TB; monitor anaphylaxis and infusion reaction, record batch, avoid unplanned combination flare therapy, and recognise limited evidence in immediate life-threatening or ICU disease.
CiclosporinFor adult severe psoriasis, use 2.5 mg/kg/day orally in two divided doses, increasing gradually if needed to no more than 5 mg/kg/day under specialist supervision.Check blood pressure, kidney function, potassium, magnesium, infection and interacting CYP3A4 medicines; reduce or stop for sustained creatinine rise or uncontrolled hypertension and plan a time-limited course.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE TA1070 spesolimab recommendationsAdult initial- and subsequent-flare eligibility, severity measures and commercial arrangement.
  • Spevigo intravenous SmPCCurrent licensed age and weight groups, 900 mg infusion and repeat dose, administration, infection, TB and evidence limitations.
  • NICE psoriasis assessment and managementUrgent specialist escalation for generalised pustular psoriasis and conventional systemic-treatment principles.
  • BAD psoriasis overviewPsoriasis inflammatory context, comorbidity and patient-facing recognition and treatment principles.
  • Ciclosporin Neoral SmPCSevere-psoriasis dosing, renal and blood-pressure monitoring, interactions and infection cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom